Aptiom (Eslicarbazepine Acetate) Patent Expiration, LOE Window & CMS Spending

Aptiom (Eslicarbazepine Acetate) by Sumitomo America: FDA Orange Book core substance LOE 2026-04-21 (last listed 2032-08-24), 9 AB generics, $270.2M 2024 CMS Part D & Medicaid spend, and 12 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSumitomo America
FDA Application & PathwayN022416 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2026-04-21
Last Listed Patent or Exclusivity Date2032-08-24
Orange Book Patents (*PED Extensions)7 patents (0 *PED)
Active AB-Rated Generic Competitors9
2024 CMS Total Public Spend$270.2M
2024 Medicare Part D Spend$144.1M
2024 Medicaid Spend$126.1M
Reported Wholesale Price Change (CA SB 17)12 WAC filings (max 20.2% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Sumitomo Pharma America across sibling Meru public-data platforms.